Zambia's national health authority providing field access and policy alignment for malaria diagnostics and sickle cell disease research in sub-Saharan Africa.
Zambia's national public health authority, responsible for disease surveillance, health policy, and the implementation of national health programmes across the country. In EU research projects, they serve as a field access and policy alignment partner — providing researchers with entry into Zambia's health system, patient populations, and real-world deployment contexts. Their H2020 participation spans two distinct disease burdens heavily prevalent in Zambia: malaria vector control and sickle cell disease. They are not a research institution, but their involvement signals regulatory legitimacy and in-country implementation credibility for any health technology targeting sub-Saharan Africa.
Participated in DMC-MALVEC (2016–2020), which developed automated diagnostic platforms and data management tools for malaria, with keywords covering mosquitoes, bednets, insecticide resistance, and integrated vector management.
DMC-MALVEC focused on molecular diagnostics and data management systems, with MOH providing the public health infrastructure needed to validate and deploy these tools in a real Zambian context.
Joined ARISE (2019–2024) as a third party, a project focused on sickle cell disease education, stroke prevention, nephropathy, and population genetics in Africa.
DMC-MALVEC explicitly includes database and data management components, areas where MOH's national health data systems would be directly relevant.
In their earlier H2020 participation (2016–2020), MOH's focus was firmly on infectious disease — specifically malaria, vector biology, insecticide resistance, and the digital tools to manage these at a population level. By 2019–2024, their involvement shifted toward non-communicable genetic disease, specifically sickle cell disease, including its complications (nephropathy, stroke) and the underlying population genetics. This is not a pivot away from infectious disease, but rather a broadening of scope to reflect Zambia's dual disease burden — a country where both malaria and hereditary haemoglobin disorders remain major public health challenges.
MOH appears to be expanding its engagement from purely infectious disease research toward hereditary and chronic conditions, which aligns with a broader global health trend of African ministries addressing the rising burden of genetic and non-communicable diseases alongside endemic infections.
MOH has never coordinated an H2020 project — they join as a participant or third party, which is expected for a government ministry in a non-EU country. They contribute institutional access, regulatory standing, and population-level reach rather than driving the scientific agenda. Their 29 unique partners across 16 countries in just two projects suggests they entered large, diverse international consortia rather than small bilateral collaborations.
MOH has connected with 29 unique consortium partners across 16 countries through only two projects, indicating involvement in broad, multi-partner international consortia. Their network is likely composed of European research universities, African health institutions, and international public health organisations.
As Zambia's national Ministry of Health, MOH offers something no research institute can replicate: legitimate governmental access to Zambia's public health system, patient populations, and national disease registries. For any consortium developing health technologies intended for deployment in sub-Saharan Africa, MOH provides the policy linkage and in-country credibility that moves a project from research to real-world impact. Their dual disease focus — infectious (malaria) and genetic (sickle cell) — reflects Zambia's actual disease profile, making them a grounded and contextually relevant partner rather than a token African affiliate.
